Back to Archived News
MMRGlobal Revives Five Material Biotech Patent Applications
Friday, November 12, 2010
Los Angeles, CA -- MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) today announced that it has successfully revived five U.S. biotech patent applications, bringing the Company closer to its goal of patent protection for all its B-cell vaccine and anti-CD20 antibody related intellectual property acquired during the Company's reverse merger with Favrille, Inc. The Company has been working to perfect the patent condition of its biotech assets for more than a year and these are part of its U.S. patent portfolio. MMRGlobal also has patent applications pending in 13 foreign countries of commercial interest that provide competitive advantages for this biotechnology, including its Specifid vaccine.
The subject patent applications specifically include protection for anti-CD20 antibodies, methods of treating B-cell lymphomas using anti-CD20 antibodies, manufacturing methods for idiotype vaccines to treat B-cell pathologies, methods for treating B-cell malignancies with vaccines, and methods for using the vaccines as combinational therapies with chemotherapeutic agents. In addition, as previously announced, the Company has been issued U.S. Patent No. 6,911,204 for methods of treating B-cell mediated malignancies. These assets relate to MMRGlobal's pre-merger clinical FavId and Specifid vaccine trials, during which time it spent in excess of $200 million to develop vaccines to treat lymphoma.
Robert H. Lorsch, MMRGlobal Chairman and CEO, said, "These patents represent additional opportunities to recoup our costs through licensing and strategic business opportunities with universities, pharmaceutical companies and others who might utilize these assets in the development of similar cancer fighting vaccines and therapies."
Prior to the merger and unbeknownst to the former Favrille Board and the Company, the patent prosecution of its biotech assets was terminated. Upon learning of the termination(s), the Company immediately began diligent efforts to reinstate these assets for the benefit of shareholders.
About MMRGlobal, Inc.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (MMR), provides secure and easy-to-use online Personal Health Records (PHRs) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. MMRGlobal's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as "need," "possibility," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," "help" and "continue," or the negative of such terms and other comparable terminology. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.'s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related but not limited to changes in MMRGlobal, Inc.'s business prospects, its results of operations or financial condition, government regulation and changes in healthcare initiatives, developing and defending its intellectual property rights including those pertaining to the Company's biotechnology assets, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.'s public filings with the U.S. Securities and Exchange Commission.
Back to Archived News